With the median cost of new oncology drugs over $260,000, it’s no wonder payers continue to look for opportunities to...
Momentum is building for more state legislators to have health insurance companies pay for biomarker testing for patients with cancer....
The No Surprises Act (NSA) has been in effect for the last few months, with most of its provisions implemented...